Isoprenylcysteine carboxylmethyltransferase-based therapy for Hutchinson–Gilford progeria syndrome
Citations Over Time
Abstract
ABSTRACT Progerin is a mutant prelamin A variant that causes Hutchinson–Gilford progeria syndrome (HGPS, progeria), a rare genetic disease characterized by premature aging and death in childhood. Although several therapeutic approaches have been explored in experimental models, clinical trials have shown very limited benefits in HGPS patients. Here, we describe the development of UCM-13207, a new potent inhibitor of isoprenylcysteine carboxylmethyltransferase (ICMT) that reduces progerin nuclear accumulation and ameliorates the typical alterations in progeroid human and mouse cells. UCM-13207 also improves phenotypic anomalies and extends lifespan in progerin-expressing Lmna G609G/G609G mice. These results support the potential use of UCM-13207 as a new treatment for progeria.
Related Papers
- → Hutchinson–Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody(2006)195 cited
- → Molecular insights into the premature aging disease progeria(2016)109 cited
- → Gene-rich chromosomal regions are preferentially localized in the lamin B deficient nuclear blebs of atypical progeria cells(2015)42 cited
- → Aging and nuclear organization: lamins and progeria(2004)93 cited
- The genetic mechanism that links Hutchinson-Gilford progeria syndrome to physiological aging.(2014)